Payment overview · 2025
General Payments
$210.64
10 reported records · 6 companies
Healthcare provider profile · identity verified
Beth Ann Schroeder, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · IRON MOUNTAIN, MI · NPI 1184616013
Verified facts
What the public records show
CMS Open Payments records show Beth Ann Schroeder, M.D. received $210.64 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 37.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Nurtec Odt.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $78.61 | 37.3% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $40.76 | 19.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.00 | 17.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.39 | 10.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.60 | 7.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.28 | 7.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $210.64 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $64.58 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $64.58 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $40.76 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $40.76 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.00 | 2 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $26.89 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $13.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 137 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
137 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 703 | 165 |
| Levothyroxine Sodium | Levothyroxine Sodium | 418 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 358 | 68 |
| Lisinopril | Lisinopril | 310 | 72 |
| Losartan Potassium | Losartan Potassium | 277 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 264 | 65 |
| Omeprazole | Omeprazole | 251 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 44 |
| Metformin Hcl | Metformin Hcl | 184 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 158 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 26 |
| Eliquis | Apixaban | 137 | 22 |
| Allopurinol | Allopurinol | 131 | 28 |
| Gabapentin | Gabapentin | 119 | 29 |
| Buspirone Hcl | Buspirone Hcl | 118 | 22 |
| Sertraline Hcl | Sertraline Hcl | 113 | 23 |
| Furosemide | Furosemide | 105 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 22 |
| Montelukast Sodium | Montelukast Sodium | 91 | 20 |
| Potassium Chloride | Potassium Chloride | 90 | 22 |
| Carvedilol | Carvedilol | 81 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 78 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 16 |
| Trazodone Hcl | Trazodone Hcl | 71 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 24 |
| Mirtazapine | Mirtazapine | 67 | 13 |
| Atenolol | Atenolol | 63 | 15 |
| Simvastatin | Simvastatin | 59 | 16 |
| Famotidine | Famotidine | 58 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 14 |
| Donepezil Hcl | Donepezil Hcl | 55 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 52 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 12 |
| Trulicity | Dulaglutide | 51 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 50 | suppressed |
| Meloxicam | Meloxicam | 48 | 18 |
| Metformin Hcl Er | Metformin Hcl | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 11 |
| Ozempic | Semaglutide | 43 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 15 |
| Jardiance | Empagliflozin | 41 | suppressed |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 36 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | 11 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Prednisone | Prednisone | 28 | 13 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 27 | 27 |
| Cephalexin | Cephalexin | 26 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Nystatin | Nystatin | 25 | 12 |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Azithromycin | Azithromycin | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Sure Comfort | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $210.64 · 10 records | ABBVIE INC. | AJOVY, CAPVAXIVE, ELIQUIS, ENFLONSIA, GARDASIL 9, NURTEC ODT, QULIPTA, REXULTI, The Cologuard Plus Collection Kit, UBRELVY, VAXELIS, VRAYLAR, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error